FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1

On September 22, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab (Keytruda, Merck & Co., Inc., Whitehouse Station, NJ) for the treatment of patients with recurrent, locally advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenoca...

Descripción completa

Detalles Bibliográficos
Autores principales: Fashoyin‐Aje, Lola, Donoghue, Martha, Chen, Huanyu, He, Kun, Veeraraghavan, Janaki, Goldberg, Kirsten B., Keegan, Patricia, McKee, Amy E., Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324629/
https://www.ncbi.nlm.nih.gov/pubmed/30120163
http://dx.doi.org/10.1634/theoncologist.2018-0221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324629/
https://www.ncbi.nlm.nih.gov/pubmed/30120163
http://dx.doi.org/10.1634/theoncologist.2018-0221

Ejemplares similares